Tekla Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Tekla Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,763	Closed	-$720K	–	208
2020 Q2	$720K	Hold	9,763	–	–	0.03%	205
2020 Q1	$484K	Buy	9,763 +1,824	+23%	+$109K	0.02%	197
2019 Q4	$610K	Hold	7,939	–	–	0.02%	191
2019 Q3	$317K	Hold	7,939	–	–	0.01%	178
2019 Q2	$267K	Hold	7,939	–	–	0.01%	190
2019 Q1	$421K	Hold	7,939	–	–	0.02%	184
2018 Q4	$373K	Hold	7,939	–	–	0.02%	194
2018 Q3	$699K	Hold	7,939	–	–	0.03%	193
2018 Q2	$826K	Hold	7,939	–	–	0.03%	161
2018 Q1	$635K	Sell	7,939 -6,385	-45%	-$872K	0.02%	165
2017 Q4	$1.95M	Hold	14,324	–	–	0.08%	128
2017 Q3	$2.32M	Hold	14,324	–	–	0.08%	112
2017 Q2	$2.15M	Hold	14,324	–	–	0.08%	108
2017 Q1	$2.23M	Buy	14,324 +7,700	+116%	+$1.35M	0.09%	108
2016 Q4	$1.38M	Hold	6,624	–	–	0.06%	118
2016 Q3	$1.52M	Hold	6,624	–	–	0.06%	126
2016 Q2	$1.37M	Buy	6,624 +2,999	+83%	+$726K	0.06%	142
2016 Q1	$921K	Buy	3,625 +1,000	+38%	+$230K	0.04%	130
2015 Q4	$901K	Buy	2,625 +125	+5%	+$37.5K	0.03%	127
2015 Q3	$636K	Hold	2,500	–	–	0.02%	156
2015 Q2	$701K	Buy	+2,500	New	+$769K	0.03%	109

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Tekla Capital Management's CDTX Position: Q3 2020 in Review

Tekla Capital Management sold out of Cidara Therapeutics (CDTX) in Q3 2020, closing a stake of 9,763 shares — an estimated $720K sold.

Tekla Capital Management first reported a position in CDTX in Q2 2015 and held it in 21 quarters. The position peaked at $2.32M in Q3 2017. 66 funds tracked by Wall St. Rank hold CDTX as of Q3 2020.

Tekla Capital Management reported no remaining Cidara Therapeutics position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 9,763 Cidara Therapeutics shares in Q3 2020, an estimated $720K.
Tekla Capital Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 21 quarters.
Tekla Capital Management's Cidara Therapeutics position peaked at $2.32M in Q3 2017.
66 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.